{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-22-040700","form_type":"8-K","ticker":"ADMA","cik":"0001368514","company_name":"ADMA BIOLOGICS, INC.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.342897+00:00","generated_at":"2026-06-22T00:51:07.524020+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"ADMA Biologics Q3 revenue $41.1M (+99% YoY); raises FY2022 guidance to $145M","bullets":["Q3 revenue $41.1M (+99% YoY from $20.7M); gross profit $9.7M vs $0.4M; net loss $14.9M ($0.08 loss/share) narrowing from $17.7M.","FY2022 revenue guidance raised to ~$145M from prior $130M; reiterates profitability target no later than Q1 2024.","ASCENIV record pull-through; ongoing strategic review with Morgan Stanley; BioCenters on track for 10 FDA-licensed centers by 2023.","Long-term targets: revenue $250M+ in 2024, $300M+ thereafter; gross margins 40-50%, net income margins 20-30%."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-22-040700","json":"https://secwatch.observer/filing/0001140361-22-040700.json","markdown":"https://secwatch.observer/filing/0001140361-22-040700.md","text":"https://secwatch.observer/filing/0001140361-22-040700.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1368514/000114036122040700/0001140361-22-040700-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1368514/000114036122040700/brhc10043955_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T00:51:07.524020+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8ea7a33f7b61adcf7eda0ebda486fa3426261de4","claim":"ADMA BIOLOGICS, INC. reported the three months ended September 30, 2022 results: revenue $41.1 million. Guidance raised.","evidence_excerpt":"2 brhc10043955_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ADMA Biologics Announces Third Quarter 2022 Financial Results and Provides Business Update 3Q2022 Total Revenues Were $41.1 Million, a 99% Y-o-Y Increase Grew 3Q2022 Gross Profit to $9.7 Million, a $9.3 Million Y-o-Y Increase Raising FY 2022 Total Revenue Guidance to $145 Million From $130 Million Previously","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036122040700/0001140361-22-040700-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended September 30, 2022"},{"label":"Revenue","value":"$41.1 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}